Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home.

The team looked at 826 people with autism, intellectual disability, or other developmental delays. All were enrolled in one state Medicaid medical-home program. The study counted how many took antipsychotic medicine and how often doctors checked weight, blood sugar, and cholesterol.

Six out of ten people were on antipsychotics. Yearly metabolic checks hit 89-99 percent. That is far better than the low rates reported in earlier chart reviews.

Lunsky et al. (2012) saw similar prescribing: about half of adults got antipsychotics right after a psychiatric crisis. Their setting was crisis care, not a steady medical home, so monitoring was not tracked.

Griffin et al. (2026) zoomed in on autistic youth with ID. Again, roughly half were medicated, mostly off-label. The new data extend that picture by showing high monitoring can go hand-in-hand with high prescribing.

Nickerson et al. (2015) followed aggressive adults with ID who stayed on high-dose antipsychotics for six months. Behavior improved only slightly, raising the question of whether the drugs were needed. Eussen et al. (2016) do not answer that question, but their tight monitoring gives teams a ready tool to re-evaluate benefit versus risk.

You now have proof that metabolic monitoring can top 90 percent in a real-world Medicaid program. Use this as a benchmark when you audit charts or speak with prescribers. High monitoring should be the rule, not a bonus, while we work to reduce unnecessary antipsychotic use.